Choroid Laboratories

Choroid Laboratories is a preclinical-stage biotechnology company focused on developing novel therapeutics for retinal degenerative diseases, particularly geographic atrophy (GA) and age-related macular degeneration (AMD). The company's core technology centers on 'Kamuvudines,' a class of small molecule drugs designed to block the NLRP3 inflammasome and prevent the toxic accumulation of Alu RNA in the retina. Founded by Dr. Jayakrishna Ambati, the company leverages breakthrough research into the molecular mechanisms of retinal pigment epithelium (RPE) cell death. Choroid Laboratories aims to address significant unmet needs in ophthalmology by providing disease-modifying oral or injectable treatments that preserve vision. Their approach represents a paradigm shift in treating dry AMD by targeting innate immune pathways rather than the complement system.